A New Stability Indicating RP-HPLC Method Development and Validation for the Simultaneous Estimation of Dolutegravir and Rilpivirine in Bulk and its Dosage Forms Stability indicating analytical method for simultaneous estimation of Dolutegravir and Rilpivirine by RP-HPLC
Iranian Journal of Pharmaceutical Sciences,
Vol. 15 No. 4 (2019),
1 October 2019
,
Page 53-72
https://doi.org/10.22037/ijps.v15.40454
Abstract
The objective of the work is to develop and validate a new, simple, highly sensitive, stability indicating RPHPLC method for simultaneous estimation of Dolutegravir and Rilpivirine in bulk and its dosage forms. The method was developed on a reversed-phase Thermosil C18 (4.6 × 150 mm, 5μm) column with an isocratic elution. The Mobile phase ratio was Acetonitrile: Phosphate Buffer pH 3.5 (45:55 % v/v). Detection was done by UV-Spectroscopy at a detection wavelength of 260 nm. The flow rate was 0.8 ml/min. The mobile phase was used as a diluent. The Injection volume was 10μl. The analytical procedure was validated as per ICH guidelines. The retention time for Dolutegravir and Rilpivirine in the standard solution having the concentration of 100 μg/ml of Dolutegravir and 50 μg/ml of Rilpivirine were observed to be around 2.427 min and 4.436 min. respectively. The purity percentage values of Dolutegravir and Rilpivirine were 99.22 % w/v and 99.81 % w/v respectively. System suitability parameters were calculated and found within the acceptance criteria. The proposed method was found to have a high degree of precision and reproducibility. Calibration plots were linear (r2> 0.999) over the concentration range of 80 - 120 μg/ml for Dolutegravir and 30 - 70 μg/ml for Rilpivirine.The recovery percent were within the acceptance criteria of 98 – 102 % for Dolutegravir and Rilpivirine. The LOD was 0.044 μg/ml for Dolutegravir and 0.060 μg/ml for Rilpivirine. The LOQ was 0.134 μg/ml for Dolutegravir and 0.183 μg/ml for Rilpivirine. The method represents a fast-analytical procedure and stability indicating analytical method for the simultaneous estimation of Dolutegravir and Rilpivirine in bulk and its dosage forms. No interference from any component of pharmaceutical dosage form was observed. Validation studies revealed that the method is specific, rapid, reliable, and reproducible. The method is amenable to the routine analysis of large numbers of samples with good precision and accuracy.
- Dolutegravir
- ICH
- Reverse transcriptase inhibitor
- Rilpivirine
- RP-HPLC
- Stability indicating method
- UV-Spectroscopy
How to Cite
References
[2] McCormack P. Dolutegravir. A review of its use in the management of HIV-1 infection in adolescents and adults. Drugs. (2014) 74 (11):1241–1252.
[3] Rik Schrijversa, Belete Ayele Desimmiea, Zeger Debysera, Rilpivirine. A step forward in tailored HIV treatment. Lancet. (2011) 378 (9787): 201–203
[4] Walmsley SL, Antela A, Clumeck N.Dolutegravir, Abacavir and Lamivudine for the treatment of HIV-1 infection. N. Engl. J.Med. (2013) 369 (19): 1807–1818.
[5] Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G and Rimsky LT. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant IV-1.Antimicrob. Agents Ch. (2010) 54 (2): 718–727.
[6] Fulco P.P, McNicholl I.R. Etravirine.Rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strain resistant to previous nonnucleoside agents.
Pharmacotherapy (2009) 29 (3): 281–294.
[7] Sharma M, Saravolatz L.D. Rilpivirine: A new nonnucleoside reverse transcriptase inhibitor. Chemotherapy (2013) 68 (2): 250–256.
[8] FDA.; Food and Drug Administration.FDA approves a new drug to treat HIV infection.http://www.fda.gov/NewsEvents/Newsroom/Pr essAnnouncements/ucm364744.html.Aug. 12,2013.
[9] Sharma.B.K. Instrumental Methods of Chemical analysis. 25th edition., Goel Publishing House Meerut, (2006) 286 - 288.
[10] Willard HH, Merritt LL, Dean JJA, Frank AS. Instrumental Method of Analysis.9th edition., CBS Publishers and Distributors,New Delhi. (1986) 580, 626.
[11] ICH Stability Testing of New Drug Substances and Products Q1A (R2). International Conference on Harmonization.IFPMA. Geneva, (2003) 1-20.
[12] Reynolds D.N, Facchine K.L, Mullaney J.F, Alsante K.M, Hatajik T.D, Motto M.G. Available guidance and best practices for conducting forced degradation studies. Pharm.Technol. (2002) 26 (2): 48–56.
[13] Jomol Joseph, N.J.R. Hepsebah, K.Deepthi. Analytical method development and validation for the simultaneous estimation of Dolutegravir and Rilpivirine using RP-HPLCm method in both bulk and pharmaceutical dosage forms. European j. biomed. pharm..(2016) 3 (5): 237-243.
[14] Kavitha K.Y, Geetha G, Hariprasad.R, Venkatanaraynan R, Kaviarasu M. Development and validation of RP-UPLC analytical method for simultaneous estimation of Emtricitabine, Rilpivirine, Tenofovir disoproxil fumarate and its pharmaceutical dosage forms. Int. Res. J. Pharm. (2013) 4 (1):150-155.
[15] Gregoire.M, Deslandes.G, Renaud.C, Bouquie.R. A liquid chromatography-Tandem Mass Spectrometry Assay for Quantification of Rilpivirine and Dolutegravir in Human Plasma. Chromatography (2014) 971: 1- 9.
[16] Somaubhra Ghosh, SowjanyaBomma, V.Laxmi Prasanna, S. Vidyadhar, David Banji, Subhadip Roy. Method development and validation of Rilpivirine in bulk and tablet dose form by RP-HPLC method. Res. J.
Pharm. Technol. (2013) 6 (3): 240-243.
[17] BhavarGirijaBalasaheb, Aher Kiran Balasaheb, Thorat Ravindra Subhash, KakadsachinJijabapu, Pekamwar Sanjay Sudhakar. Development and validation of UV spectrophotometric method for estimation of
Dolutegravir sodium in tablet dosage form.Malaysian J. Anal. Sci. (2015) 19(6): 1156-1163.
[18] Xinzhu Wang, Sujan Dilly Penchala. A validated method for quantification of Dolutegravir using ultra performance liquid chromatography coupled with UV detection.Ther. Drug Monit. (2016) 38 (3): 327-332.
[19] Abhijit A. Dale, Annemarie Shibata, Patrick Bruck. Development and validation of a simple and isocratic RP-HPLC method for the determination of Rilpivirine from tablets, nanoparticles and HeLa cell lysates. Biomed.Chromatogr. (2015) 29 (5): 709-715.
[20] Bhavar G.B, Pekamwar S.S, Aher K.B, Chaudhari S.R. Development and validation of UV Spectrophotometric method for estimation of Rilpivirine hydrochloride in bulk and pharmaceutical formulations. American Journal of Pharm. Tech. Res. (2013) 3 (1): 450 – 458.
[21] FDA: Guidance for Industry.Analytical Procedures and Methods Validation. August 2000.http://www.fda.gov/cder/guidance/index. htm (Accessed April, 2018)
[22] International Conference on the Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Q2B.Validation of Analytical Procedures, Methodology. (1996)1-13.
[23]. Ching. Chowchan, Lee.Y.C, Hernan Lam, Xue-Ming Zhang. Analytical Method Validation and Instrument Performance Verification. 5th Edition., A John Wiley & Sons, Inc, Publications (2004) 27 - 29.
[24] Frank Settle.Instrumental Techniques for Analytical Chemistry. Prentice Hall, 3rd edition, (1997) 73 - 74.
[25] Garry D. Christian.Analytical Chemistry.6th edition, John Wiley and Sons, (2003) 126 -133.
[26] Nagasarapu Mallikarjuna Rao, Dannana Gowri Shankar. Development and validation of stability-indicating HPLC method for simultaneous determination of Lamivudine, Tenofovir and Dolutegravir in bulk and their tablet dosage form. Future J. Pharm. Sci..(2015) 1 (2): 73-77.
[27] Saidulu P, Mastanamma Sk. Stability indicating gradient RP-HPLC method for the simultaneous estimation of Lamivudine, Abacavir and Dolutegravir in bulk and their combined dosage form. Int. J. Pharm. Sci.Rev. Res. (2016) 37 (2): 249-257.
[28] Sindhu Priya, D. Gowri Sankar.Simultaneous stability-indicating method for the determination of Abacavir, Dolutegravir and Lamivudine by RP-HPLC. Int. J. Pharm.Sci. (2016) 7 (7): 2905-2916.
[29] BrahmaiahMarineni, Vangala Krishna,T. Sreenivasulu Reddy. A validated stability indicating HPLC assay method for Rilpivirine hydrochloride in bulk drug. Int. J. Pharm.Biol. Sci. (2013) 3 (4): 278-287.
[30] Mohanareddy C, Hussain Reddy K,Narayanareddy P,Venkataramana M.Degradation pathway for Rilpivirine indicating UPLC method. Int. J. Clin Pharmacol Ther. Toxicol. (2012) 1(1):1-8.
[31] S.Venkatesan, N. Kannappan, Sai Sandeep Mannemala. Stability-indicating HPLC method for the simultaneous determination of HIV tablet containing Emtricitabine, Tenofovir disoproxil fumarate
and Rilpivirine hydrochloride in pharmaceutical dosage forms. Int. Sch. Res.Notices. (2014): 1-9. Article ID 849149http://dx.doi.org/10.1155/2014/849149.
[32] Girija B. Bhavar, Sanjay S Pekamwar,Kiran B. Aher, Ravindra S. Thorat and Sanjay R Chaudhuri. High performance liquid chromatography and High-performance thin layer chromatographic method for the
quantitative estimation of Doutegravir sodium in bulk drug and pharmaceutical dosage form.Scientific pharmaceutica. (2016) 84 (2): 305-320.
[33] Burugula L, Pilli NR, Makula A,Lodagala DS, Kandhagatla R. Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor Rilpivirine in human plasma. Biomed. Chromatogr. (2013) 27 (2):172–178.
[34] Kavitha K.Y, Geetha G, Hariprasad.R, enkatanaraynan R, Kaviarasu M.Development and validation of RP-UPLC analytical method for simultaneous estimation of Emtricitabine, Rilpivirine, Tenofovir
disoproxil fumarate and its pharmaceutical dosage forms. Int. Res. J. Pharm. (2013) 4 (1):150-155.
[35] Pranitha D, Vanitha C, Francies P.Simultaneous estimation of Emtricitabine,Tenofovir disoproxil fumarate and Rilpivirine Res. (2012) 5 (8): 4600–4602.
[36] Sandeep Reddy Katla, Venisetty Raj Kumar, Sridhar Thota. Estimation of rilpivirine in bulk and pharmaceutical dosage form. Der Pharm. (2014) 6(1): 146-151.
[37] Somaubhra Ghosh, SowjanyaBomma, V.Laxmi Prasanna, S. Vidyadhar, David Banji,Subhadip Roy. Method development and validation of Rilpivirine in bulk and tablet doses form by RP-HPLC method. J. Pharm.Technol. (2013) 6(3): 240-243.
[38] Sudha T, Shanmugasundram P. Reverse phase high performance and HPTLC methods for the determination of Rilpivirine bulk and in tablet dosage form. World J. Pharm. Res.(2012) 1(4):1183–1196.
- Abstract Viewed: 401 times
- IJPS_Volume 15_Issue 4_Pages 53-72 Downloaded: 193 times